Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Camptoo is a web application by which travellers can rent a motorhome straight from the owner. Its users can easily rent any of the available 3,000+ vehicles offered in fifteen countries. This company turned motorhome ownership into a revenue-making venture instead of an expensive hobby. More than 50,000 users have experienced travelling using Camptoo, and its number is growing year on year. It was part of the Google Launchpad accelerator program in 2015. Furthermore, in the Netherlands, it was awarded 'most promising startup' by Deloitte Technology Fast50 Jury in 2017, and in Europe, '16th fastest growing tech company' by TheNextWeb in 2018. With the proceeds, this company will further accelerate marketing campaigns in Australia and the UK and further optimize its current web application.
days to go:
Expired
investment:
£476,642
HealthBox Software is a technology company building products for the post-COVID healthcare landscape. Its first product, ClearPass, was met with success. The tool asks an employee a series of screening questions related to COVID-19, including evidence of fever, fatigue, and dry cough, etc. ClearPass has over 400,000 end-users including companies like Johnson Controls, Remy Cointreau and the San Diego School District. HealthBox aims to be a significant contender in the global digital health market that is expected to be worth $600 billion by 2026. The company is on the verge of launching another innovative product, MyHealthBox. It is a consumer-facing digital health app that will allow users to store their medical records, easily accessible 24/7. HealthBox asserts that the app will have an array of features, including AI health assessment services, dietary advice and data-powered lifestyle guidance. The company will use 47% of the investment towards technology and development costs, and 53% towards sales and marketing.
days to go:
Expired
investment:
£144,265
Clinical Net is a health-tech firm focused on revolutionizing access to innovative clinical trials. Their AI platform swiftly connects patients with suitable trials, addressing the challenge of low participation rates and delays that hinder pharmaceutical research. With over 69,000 trials globally, their solution aims to streamline the cumbersome and time-consuming process of trial matching, making it more efficient and accessible within 5 minutes. This innovative approach targets the $3.73 billion patient recruitment market while ensuring individuals have easier access to groundbreaking treatments.
days to go:
Expired
investment:
£136,827
Evaclite manufactures dynamic exit signs designed to make buildings safer and save lives. The company argues that its products are 77% more visible than conventional exit signs and reduces congestion at exits by 36%. The company received the 2018 FIREX - Fire Innovation of the Year Award. It also won the Safety and Health Excellence (SHE) Award in 2019 and 2020. Evaclite counts companies like Apple, CBRE, BBC, Melia, and MetroBank amongst its clients. The company has inquiries from over a dozen countries globally with a 12-month sales opportunity pipeline of over £1.5 million. It will use 60% of the investment to build its sales team, 28% to boost its inbound marketing campaign, 7% to develop additional intellectual property, and 5% towards overhead and general costs.
days to go:
Expired
investment:
£148,736
A car-sharing platform for drivers to receive an extra income by allowing the local community to drive their cars instead of leaving it idle and unused. Hiyacar has a acquired an exclusive insurance product with AXA and already has more than 2,000 cars enrolled, with the majority located in London and surrounding urban areas with the intention of expanding further in the future.
days to go:
Expired
investment:
£1,431,885
Brompton's bicycle hire allows people to hire folding bicycles from hiring stations. The hiring stations (docks) are sold to partners. The company have already sold 44 docks to partners. They are looking for investment to prepare the business for international expansion. The funding will used to increase the size of their network by placing more docks in strategic locations. Their service will also be developed with the funds, working on their customer service and developing their skills.
days to go:
Expired
investment:
£380,000
Amino focuses on targeted nutrition using amino acids to improve human health, emphasizing the untapped potential beyond sports and bodybuilding. Currently offering pre- and intra-workout amino acid drinks, the company aims to expand its product line to cater to a broader consumer base, believing the market lacks variety in ready-to-mix powdered blends. Backed by scientific research and a commitment to taste and accessibility, Amino aspires to emerge as the leading global brand in amino acid products.
days to go:
Expired
investment:
£193,219
